U.S. markets open in 8 hours 51 minutes

GoodRx Holdings, Inc. (GDRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
39.00-1.61 (-3.96%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close40.61
Bid0.00 x 1100
Ask0.00 x 800
Day's Range38.78 - 40.95
52 Week Range33.39 - 64.22
Avg. Volume2,284,575
Market Cap15.293B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    3 Growth Stocks That Could Be Great Long-Term Investments

    These three growth stocks are down big. The decline in stock price could mean a great buying opportunity for long-term investors.

  • These 3 Stocks Are Absurdly Overvalued Right Now
    Motley Fool

    These 3 Stocks Are Absurdly Overvalued Right Now

    One of the dangers of investing right now is that there are many high-priced stocks out there. GoodRx's business makes it easier for consumers to buy prescriptions at lower prices. GoodRx's lack of an edge is especially concerning given one of its competitors may end up being Amazon (NASDAQ: AMZN).

  • Motley Fool

    Are Ultra-High Drug Prices Sustainable?

    Goodrx (NASDAQ: GDRX) recently released its list of the 10 most expensive drugs on the market. Novartis' (NYSE: NVS) gene therapy Zolgensma remains at the top, but newcomers Eiger Pharmaceuticals (NASDAQ: EIGR) and Y-mAbs Therapeutics (NASDAQ: YMAB) took second and third place with Zokinvy and Danyelza, respectively. In this video from Motley Fool Live, recorded on March 15, Fool.com Contributors Brian Orelli and Keith Speights discuss the high-priced drugs and whether the prices are sustainable in the long run.